The phase 3 EXCALIBER-RRMM trial supports iberdomide plus daratumumab and dexamethasone as a new standard of care in relapsed ...
C. Ola Landgren, MD, PhD, discusses disparities in myeloma care access between academic and community practices and how his center works to bridge that gap.
In the phase 3 CERVINO trial, etentamig showed an early overall survival signal in patients with triple-class exposed relapsed/refractory multiple myeloma. Etentamig, a BCMA/CD3 bispecific antibody, ...
Hans C. Lee, MD, discussed how he monitors patients with multiple myeloma who achieve deep, sustained MRD negativity after coming off therapy.
No new safety signals were observed with the daratumumab regimen after an additional 3 years of follow-up in the phase 3 ...
Ludmir, MD, discussed neoadjuvant radiation, advanced treatment techniques, the HYPERION CCA trial, and lirafugratinib in ...
TriNav Advance is the fourth FDA-cleared PEDD device in TriSalus’s portfolio, joining the TriNav Infusion System and TriNav ...
Elizabeth Thompson, MD, discusses pediatric cancer, proton therapy, and her work as a peer reviewer for CURiE. In an ...
The FDA granted priority review to perioperative durvalumab plus enfortumab vedotin for cisplatin-ineligible muscle-invasive disease, based on phase 3 VOLGA data.
Time to worsening of symptoms was improved with amivantamab plus chemotherapy compared with chemotherapy alone in the phase 3 ...
Three nurses discuss the differences in the care and education required for patients with first-line EGFR-mutated non–small ...
Meletios A. Dimopoulos, MD, explored how anselamimab’s benefit in kappa light chain amyloidosis fits into the evolving role of anti-fibril therapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results